Skip to main content

Table 2 Morphological, biochemical, and symptomatic response in patients

From: Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas

Response criteria

Response (N)

Morphological response (N = 25)

 Partial remission

7 (28%)

 Stable disease

14 (56%)

 Progressive disease

4 (16%)

Biochemical response (CgA) (N = 25)

 < 25% reduction

12 (48%)

 25–50% reduction

4 (16%)

 > 50% reduction

7 (28%)

 Increase in CgA

2 (8%)

Symptomatic response (anti-hypertensive drugs) (N = 14)

 Reduction of anti-HTN drugs

6 (43%)

 No change

8 (58%)